Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies – guidance (TA704)

NICE recommend trastuzumab deruxtecan for use within the Cancer Drugs Fund for HER2+ve unresectable or metastatic breast cancer in adults after 2 or more anti‑HER2 therapies. It is recommended only if the conditions in the managed access agreement are followed.

National Institute for Health and Care Excellence